RIGI and leukemia: Although RIG-I signaling has been involved in anticancer immunity in several tumors, such as pancreatic cancer, hepatocellular carcinoma, leukemia, breast cancer, and melanoma, its role in HPV-associated cancers is still unknown [6–10].